After nearly 60 years of successful eradication in the United States, the New World screwworm (Cochliomyia hominivorax) has reemerged in North America, prompting renewed surveillance and containment efforts due to its ability to infest and destroy living tissue in animals and humans.
While Americans are being affected by Ebola and Hantavirus, the federal government has made concerted efforts to decrease biopreparedness programs, including reducing funding, and downsizing personnel who study and address high-consequence infectious diseases (HCID). Despite these efforts, the US has had protocols, infrastructure, and medical personnel in place to deal with these current situations.
Invivyd has dosed the first participants in LIBERTY, a phase 3 trial comparing VYD2311 to an mRNA COVID vaccine and coadministration, as the BLA-enabling DECLARATION trial completes enrollment.
Joanne D. Stekler, MD, MPH, discusses why many Americans still miss HIV diagnosis—and how opt-out screening, rapid tests, self-tests, and same-day treatment close the gap.
Meta-analysis finds approximately 1% of well-appearing outpatient infants aged 60 to 90 days with fever have an invasive bacterial infection.
The American Society for Microbiology (ASM) is leveraging its new phage therapy coordination efforts to connect researchers and clinicians, standardize approaches, and explore how bacteriophages could complement antibiotics in the fight against antimicrobial resistance. Colleen Kraft, MD, offers some insights on the organization's plans to help grow this medical modality.
A new multiplex blood-screening assay is streamlining transfusion safety by enabling simultaneous detection and discrimination of HIV, HBV, HCV, and hepatitis E in a single test, helping laboratories improve efficiency, reduce turnaround times, and strengthen blood supply resilience amid ongoing donation and staffing shortages. Nico Michel, PhD, of Roche Diagnostics, offers insights on this diagnostic.
A once-weekly oral HIV treatment combining islatravir and lenacapavir achieved its primary efficacy endpoint in 2 phase 3 trials, bringing the investigational regimen closer to becoming the first approved long-acting oral HIV therapy.
A novel antimicrobial susceptibility testing platform, ATB Finder, is designed to improve treatment outcomes by evaluating antibiotics under conditions that closely mirror the infection site and microbial communities found in patients. George Tetz, MD, PhD, offers insights on this platform.
The FDA's accelerated approval of this therapy provides the first approved treatment option for chronic hepatitis delta in the US. Anu Osinusi, MD, discusses how this targeted therapy is designed to slow disease progression and improve patient outcomes.
American Society for Microbiology (ASM) CEO Stefano Bertuzzi, PhD, MPH, discusses how they are reorganizing its structure to create more focused scientific divisions while maintaining collaboration across disciplines and improving member engagement.
Kelly Oakeson, PhD, explains how Utah public health officials are leveraging a statewide wastewater surveillance system to monitor measles activity, identify emerging outbreaks, and supplement traditional case reporting.
New data on flu vaccine for children counter the contention that a lack of contemporaneous randomized data justifies its removal from recommended annual immunizations.
Why people with HIV age faster: Kristine Erlandson, MD, offers expert tips on frailty, HAND screening, statins post-REPRIEVE, and avoiding ART drug interactions.
An increase in Plasmodium vivax malaria in New York City follows trends in migration from regions where it is endemic.
Effectiveness of post-exposure prophylaxis (PEP) with doxycycline for chlamydia and syphilis comes with increase in resistant gonorrhea.
PolyPid has completed its New Drug Application submission to the FDA for D-PLEX100, a novel locally administered antibiotic therapy that significantly reduced surgical site infections in a phase 3 trial and could receive a regulatory decision in early 2027.
The FDA has approved ensitrelvir (Xocova) for postexposure prophylaxis of COVID-19 in adults and children 12 years or older, making it the first and only oral antiviral authorized to help prevent symptomatic infection after exposure.
Modeling of the ACIP recommendation to replace universal birth-dose HepB vaccination with vaccination based on "shared decision" and maternal status shows substantially more maternal screening or vaccinating infants of unscreened mothers will be necessary to mitigate increase in infections.
Traws is studying an oral combination antiviral for hantavirus and Ebola, but no animal or human efficacy data have been reported.
Fluoroquinolones are broadly active and convenient, but black box warnings and resistance concerns have reshaped when and how clinicians should use them.
A 12-month longitudinal analysis of 852 children found two-thirds of those with confirmed SARS-CoV-2 infection reported at least one of 20 post-COVID symptoms, with anxiety and depression equally prevalent in uninfected peers.
A 5-day course of nitrofurantoin was found superior to single-dose fosfomycin for uncomplicated UTI in women, prompting investigators to recommend choosing efficacy over convenience.
In the second episode with Emory’s Gavin Harris, MD, he offers some insights about treating patients with the Andes virus, including supportive care as well as investigational antivirals.
Incoming SIDP President Lisa Dumkow, PharmD, FIDP, BCIDP, highlighted plans to expand mentorship, strengthen research collaboration, and move the organization's initiatives forward. She also offered insights into the new combined MAD-ID/SIDP meeting.
At the MAD-ID and SIDP 2026 annual meeting, Zachary Nelson, PharmD, MPH, BCIDP, discussed how urine-specific breakpoints can improve treatment decisions for urinary tract infections by accounting for drug concentrations in the urinary tract rather than relying solely on traditional blood-level interpretations.
Editor-in-Chief Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, discusses how a coalition of major medical professional societies needed to step in to sue the federal government after sweeping changes to US vaccine policy under Health and Human Services Secretary Robert F. Kennedy Jr. reshaped the CDC’s vaccine advisory process. The medical organizations argued that the evidence-based foundations of public health recommendations had been compromised.
C difficile deaths drop after 2011, but seniors, Black Americans, and rural areas still see higher mortality.
Emory’s Gavin Harris, MD, discusses how getting patients this type of treatment is essential to reducing the severity of disease, as well as adapting the four “I’s” algorithm in dealing with high-consequence infectious disease outbreaks.
The FDA has approved bulevirtide-gmod (Hepcludex), the first approved US therapy for HPDV with no prior treatment options.
